Thioridazine prolongs the cardiac QT interval more than any other antipsychotic, rendering it too risky for the majority of patients.

Pimavanserin is the only antipsychotic with virtually no dopamine receptor activity.

Perphenazine, first introduced in 1957, is an older first-generation antipsychotic (FGA) that became newly popular after the 2005 CATIE trial showed it to be as effective as most second-generation antipsychotics (SGAs) with minimal weight gain or metabolic problems. Many clinicians now consider it an effective, well tolerated, inexpensive alternative to SGAs.

Paliperidone is the active metabolite of risperidone.

Molindone is an effective, well-tolerated first-generation antipsychotic (FGA) of medium potency—a solid medication favored by some clinicians for select patients. It was recently reintroduced to the market and remains generic and inexpensive.

Lumateperone is the newest second-generation antipsychotic, approved for adults with schizophrenia or bipolar depression.

Haloperidol is an effective, inexpensive first-generation antipsychotic (FGA) with low weight gain potential and a long history of use, but its clinical utility is limited by extrapyramidal symptoms (EPS) and the risk of tardive dyskinesia.

Fluphenazine is an effective, inexpensive first-generation antipsychotic (FGA) with a long history of use, but its utility is limited in some patients due to extrapyramidal symptoms (EPS) and the risk of tardive dyskinesia.

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information